二线疗法和挽救疗法
多种药物对霍奇金淋巴瘤有活性，包括组蛋白脱乙酰基酶 (HDAC) 抑制剂[84]Adams H, Obermann EC, Dirnhofer S, et al. Targetable molecular pathways in classical Hodgkin's lymphoma. Expert Opin Investig Drugs. 2011;20:141-151.http://www.ncbi.nlm.nih.gov/pubmed/21204722?tool=bestpractice.com（例如，帕比司他 (panobinostat)、[85]Sureda A, Younes A, Ben-Yehuda D, et al. Final analysis: phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant. American Society of Hematology Annual Meeting Abstracts. 2010;116:419.恩替诺特 (entinostat) 和[86]Younes A, Hernandez F, Bociek RG, et al. The HDAC inhibitor entinostat (SNDX-275) induces clinical responses in patients with relapsed and refractory Hodgkin’s lymphoma: results of ENGAGE-501 multicenter phase 2 study. 53rd ASH Annual Meeting and Exposition, San Diego; 2011.莫西司他 (mocetinostat)[87]Younes A, Bociek RG, Kuruvilla J, et al. Mocetinostat (MGCD0103), an isotype-selective histone deacetylase (HDAC) inhibitor, produces clinical responses in relapsed/refractory Hodgkin lymphoma (HL): update from a phase II clinical study. 52nd ASH Annual Meeting and Exposition, Orlando; 2010.、哺乳动物类雷帕霉素靶蛋白 (mammalian target of rapamycin, mTOR) 抑制剂（例如，依维莫司[88]Johnston PB, Pinter-Brown L, Rogerio J, et al. Open-label, single-arm, phase II study of everolimus in patients with relapsed/refractory classical Hodgkin lymphoma. American Society of Hematology Annual Meeting Abstracts. 2011;118:2717.）以及来那度胺[89]Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011;118:5119-5125.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217400/http://www.ncbi.nlm.nih.gov/pubmed/21937701?tool=bestpractice.com和苯达莫司汀 (bendamustine)。[90]Moskowitz A, Hamlin P, Gerecitano J, et al. Updated results of a phase II trial of bendamustine in relapsed and refractory Hodgkin lymphoma. Ann Oncol. 2011;22(suppl 4):180-181.
